ongoing trials in aml and hr-mds: enhance, enhance-2 and enhance-3
Published 2 years ago • 68 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
2:09
trends in aml and mds at ash 2021
-
1:27
the role of menin inhibitors in the treatment of hr-mds and aml
-
0:46
prolonging survival in patients with aml ineligible for intensive chemotherapy
-
2:26
enhance-2: phase iii study of magrolimab plus azacitidine in untreated tp53-mutant aml
-
1:16
an insight into the beat aml trial and the value of precision medicine
-
1:28
cd47 antibodies for the treatment of aml and mds: where is the field moving?
-
7:46
updates in aml treatment and research from asco 2023
-
2:43
magrolimab azacitidine in tp53-mutant aml
-
8:14
progress in the treatment of tp53 mutated aml
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
2:02
oral azacitidine maintenance in aml with mds-related changes: insights from quazar aml-001
-
2:09
advances in the management of fit adults with aml
-
2:11
beat aml master trial: novel precision medicine approach in aml
-
2:44
ongoing and future aml research at the valk lab
-
2:49
the role of the immune system in the pathophysiology of mds
-
6:41
clinical trials aiming to reduce the toxicity of novel agents in aml
-
2:15
phase ib/ii trial of siremadlin alone or in combination with dli in high-risk aml post-allosct
-
2:11
the current role of immuno-oncology in aml and future outlooks
-
6:00
sabatolimab plus hmas in patients with hr-mds and aml
-
1:13
the unmet needs and future of cmml treatment